

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

## EDITORIAL

### Nosocomial Pertussis in the Nineties

JAMES D. CHERRY, MD, MSc

553

## ORIGINAL ARTICLES

### Containment of Pertussis in the Regional Pediatric Hospital During the Greater Cincinnati Epidemic of 1993

CELIA D.C. CHRISTIE, MD; ANNE MARIE GLOVER, RN, BA; MARY JANE WILLKE, RN; MARY L. MARX, BA; SHIRLEY F. REISING, PhD; NANCY M. HUTCHINSON, RN, MSN

556

### Vertical Transmission of *Citrobacter diversus* Documented by DNA Fingerprinting

BRENDA S. HARVEY, MD; THEARITH KOEUTH, BSc; JAMES VERSALOVIC, PhD; CHARLES R. WOODS, MD; JAMES R. LUPSKI, MD, PhD

564

### An Outbreak of Needlestick Injuries in Hospital Employees Due to Needles Piercing Infectious Waste Containers

ANNE M. ANGLIM, MD, MS; JUNE E. COLLMER, RN, MSN, CPNP; T. JOEL LOVING, MS; KENNETH A. BELTRAN, BS; BETTY J. COYNER, RN, MSN; KARIM ADAL, MD, MS; JANINE JAGGER, MPH, PhD; NIKOLAS J. SOJKA, DVM; BARRY M. FARR, MD, MSc

570

### Recovery of Vancomycin-Resistant Enterococci on Fingertips and Environmental Surfaces

GARY A. NOSKIN, MD; VALENTINA STOSOR, MD; ISABELL COOPER, BS, MT (ASCP); LANCE R. PETERSON, MD

577

### Percutaneous Injury Analysis: Consistent Categorization, Effective Reduction Methods, and Future Strategies

DONNA J. HAIDUVEN, BSN, MSN, CIC; ESTHER S. PHILLIPS; KARL V. CLEMONS, PhD; DAVID A. STEVENS, MD

582

### Molecular Heterogeneity of *Acinetobacter baumannii* Isolates During Seasonal Increase in Prevalence

CELIA D.C. CHRISTIE, MD; DOROTHY MAZON, RN; WALTER HIERHOLZER, JR, MD; JAN EVANS PATTERSON, MD

590

## CONCISE COMMUNICATIONS

### Epidemiologic Investigation of an Outbreak of Coagulase-Negative *Staphylococcus* Primary Bacteremia in a Newborn Intensive Care Unit

LUIS F.A. CAMARGO, MD; TÂNIA M.V. STRABELLI, MD; FLORACY G. RIBEIRO, RN; ELIZA R. IWASHASHI, MD; MUNIR EBALD, MD; HÉLIO H.H.C. FILHO, MD; SUMIKO I. SINTO, BS; CAIO M.F. MENDES, MD; DAVID E. UIP, MD

595

### Treatment of Hickman Catheter Sepsis Using Antibiotic Lock Technique

ELIZABETH A. KRZYWDA, RN, BSN; DEBORAH A. ANDRIS RN, BSN; CHARLES E. EDMISTON JR, PhD; EDWARD J. QUEBBEMAN MD, PhD

596

Continued inside.

# The Real Facts About Glutaraldehyde

**G**lutaraldehyde solutions have been proven effective for over 30 years. The praise in medical circles for glutaraldehyde's efficacy and safety led to quick acceptance. Glutaraldehyde's ability to reliably disinfect and sterilize medical instruments generated high confidence. And lasting confidence. Recently, however, that confidence is being questioned in certain corners. To make an informed judgement, consider the facts presented below.

## High Level Disinfection or Sterilization?

Currently, there is universal acceptance of high level disinfection for semi-critical devices such as flexible endoscopes.<sup>†</sup> This acceptance comes from both government and professional organizations, including the FDA, CDC, AORN, APIC, SGNA, and ASGE. As one group stated, "The apparent consensus is that high-level disinfection, if meticulously and consistently done, gives a high degree of patient safety; this appears to be the current standard worldwide."<sup>1</sup>

"Although the value of sterilization of semi-critical items may seem obvious, evidence that sterilization reduces the risk of infection is lacking."<sup>2</sup> The incidence of post-endoscopic infections has been estimated to be 1 in approximately 1.8 million gastrointestinal procedures.<sup>3</sup>

## Fast Acting, Compatible, Reusable and Cost Effective

Glutaraldehyde is the most commonly used liquid chemical germicide for heat-sensitive medical devices such as endoscopes. It provides *quick high level disinfection* for fast instrument turnaround time. However, manufacturers' recommendations for specific high level disinfection times vary with formulation and usage. Their complete product directions should be referred to before use.

Data from a variety of sources clearly indicate that reducing the bioburden challenge by thorough cleaning prior to high level disinfection or sterilization results in greater efficacy in less time. For example, the APIC Guideline for

Selection and Use of Disinfectants recommends 20 minutes at room temperature as the minimum exposure time for a 2% glutaraldehyde to achieve high level disinfection following cleaning. However, because manufacturers have no control over user's cleaning technique, and regulatory agencies currently do not recognize a protocol that considers the effects of cleaning on label claims<sup>4</sup>, specific label statements *cannot* be made with regard to the potential decrease in soak time and temperature following cleaning.

Glutaraldehyde can also be used to *sterilize* heat-sensitive instruments when ETO or steam sterilization is not appropriate.

Compared to other liquid chemical germicides used for high level disinfection and sterilization, alkaline glutaraldehyde has the best *compatibility with a wide range of materials*.<sup>2</sup> It is non-corrosive to instruments, including delicate endoscopic instrumentation. Furthermore, glutaraldehyde is reusable up to 14 or 28 days.<sup>††</sup> This makes it the most *cost effective* product available for high level disinfection.

In addition, glutaraldehyde may be used in automated endoscope reprocessors to reduce health care worker exposure, and reduce the variability of processing instrumentation in manual tray systems.

## Effectiveness Can Be Tested Before Each Use

Glutaraldehyde solutions *can be tested and documented* prior to each use to verify that the effective concentration is still present. This provides the end user with a margin of safety by offering a reliable way to detect unintentional dilution or contamination of the glutaraldehyde solution.

## Hard Evidence Favors Glutaraldehyde's Safety For Health Care Workers

Although glutaraldehyde can be irritating to the eyes, respiratory tract and skin, precautions can easily be undertaken to prevent these short term effects by donning appropriate protective clothing (such as high quality rubber latex gloves, protective eye wear and fluid resistant gowns) and the implementation of environmental controls that allow for adequate ventilation.<sup>†††</sup> However, even upon exposure at ambient temperatures to vapor concentrations in excess of the 0.2 ppm threshold limit value, *no evidence of acute or subchronic toxicity has been found in studies on animal models*.<sup>5-7</sup>

"Glutaraldehyde does not meet the criteria for classification as a mutagen . . . [or] . . . carcinogen . . . A number of studies have no evidence of teratogenicity."<sup>8</sup> Studies conducted to date have shown glutaraldehyde *not to be a suspected carcinogen*. Although glutaraldehyde is frequently confused with formaldehyde, its chemical and toxicological properties are significantly different. OSHA, the International Agency for Research on Cancer (IARC), and the National Toxicology Program (NTP) do not list glutaraldehyde as a carcinogen.

In addition, studies conducted to date have shown glutaraldehyde *not to cause birth defects*.<sup>5,9</sup> However, as a normal precaution, pregnant women working around glutaraldehyde or other chemicals should inform their obstetricians.

## Prominent Endoscope Companies Recommend Glutaraldehyde<sup>††††</sup>

For over 30 years, prominent endoscope companies such as Olympus, Karl Storz, Stryker Endoscopy, CIRCON ACMI, Pentax and Fujinon have recommended alkaline glutaraldehyde solutions as safe to use with their delicate endoscopic instrumentation.

Third party studies confirm this recommendation. "In particular, they (glutaraldehyde solutions) are preferred for the disinfection of gastrointestinal endoscopes."<sup>10</sup>

## Glutaraldehyde Meets U.S. EPA Regulations For Non-Hazardous Waste

In compliance with U.S. EPA regulations, glutaraldehyde *may be disposed down the drain* as an ordinary domestic waste.<sup>††††</sup> Further, by the time the drain-disposed solutions reach the wastewater treatment system, they are diluted to well below 10 ppm glutaraldehyde. At this low concentration, glutaraldehyde will not have detrimental effects on functioning wastewater treatment systems.

The fact is, sewage microorganisms readily biodegrade glutaraldehyde, initially to glutaric acid, a naturally occurring compound, and then ultimately to carbon dioxide and water.

## The FDA Now Regulates Glutaraldehyde's Claims

The FDA now regulates the efficacy claims of high level disinfectants/sterilants. All manufacturers of high level disinfectants/sterilants used with medical devices are currently required to submit for 510(k) clearance with the FDA.

"Chemical germicides should be registered with the U.S. Environmental Protection Agency

and cleared for marketing by the U.S. Food and Drug Administration."<sup>11</sup> The FDA 510(k) clearance process assures that similar glutaraldehyde products will have comparable high level disinfection claims.

## Glutaraldehyde Is A Long-Running Success Story

Today, glutaraldehyde continues to pass one of the most important safety tests health care workers rely upon – the test of time.

## How To Get More Information

If you would like to learn more about glutaraldehyde, ask your Johnson & Johnson Medical, Inc. Account Manager about our educational programs, including *The Use of Glutaraldehyde in the Health Care Environment*, a videotape that allows for 2 contact hours, and *Just The Facts*, a publication that discusses important issues about high level disinfection and sterilization. If you would like *technical* assistance, please call 1-800-423-5850.

<sup>†</sup>Rigid endoscopes are considered to be a critical device and should be sterilized versus high level disinfected before each use, if feasible. When sterilization is not feasible, high level disinfection is acceptable. This is consistent with the Center for Disease Control guidelines for decontamination and cleaning laparoscopes, endoscopes and respiratory therapy equipment in their Department of Health and Human Services "Guidelines for Prevention and Control of Nosocomial Infection," and the "APIC Guideline for Selection and Use of Disinfectants."

<sup>††</sup> Provided the glutaraldehyde solution passes test strip verification of minimum effective concentration (MEC).


<sup>†††</sup> During the 1970s, the American Conference of Governmental Industrial Hygienists (ACGIH) adopted a threshold limit value (TLV) ceiling limit of 0.2 ppm of glutaraldehyde for the atmosphere in work environments. The ceiling limit may be achieved by "any reasonable combination of engineering controls, work practices and personal protective equipment." Code of Federal Regulations 29 C.F.R. 1910.1000 CH XVII. Strive to achieve a minimum of 10 air exchanges per hour.

<sup>††††</sup> While surfactant containing glutaraldehyde solutions are NOT generally recommended for use with rigid endoscopes used in electrosurgical procedures, major scope manufacturers have found surfactant containing glutaraldehyde solutions to be compatible with their flexible endoscopes.

<sup>†††††</sup> Please note that some state and local authorities may have additional restrictions on drain disposal of specific wastes.

1. Bond WW. Center for Disease Control, Biological Indicators for a Liquid Chemical Sterilizer: A Solution to the Instrument Reprocessing Problem? *Infect Contr Hosp Epidemiol.* 1993; 14:311.
2. Rutula W. APIC Guideline for Selection and Use of Disinfectants, *Am J Inf Contr.* p 104.
3. Transmission of Infection by Gastrointestinal Endoscopy, *ASGE.* 1993;39:885-886.
4. Rutula W. et al. FDA Labeling Requirements for Disinfection of Endoscopes: A Counterpoint. *Infect Contr Hosp Epidemiol.* 1995;231-235.
5. Ballantyne B. Review of Toxicological Studies and Human Health Effects - Glutaraldehyde, *Union Carbide Corp.* 1986:4-5.
6. Greenspan B, Ballantyne B, Fowler E, Snellings W. Subchronic Inhalation Study of Glutaraldehyde, *Toxicologist.* 1985;5:29.
7. Kari F. National Toxicology Program Technical Report on Toxicity Studies of Glutaraldehyde - Administered by Inhalation to F344/N Rats and B6C3F Mice, *NIH Publication 93-3348.* 1993.
8. Worksafe Australia. Priority Existing Chemical Number 3, Glutaraldehyde. July, 1994.
9. Ema M, Itami T, Kawasaki H. Teratological Assessment of Glutaraldehyde in Rats by Gastric Intubation, *Teratology Letters.* 1992;63:147-153.
10. Bailly JL. Activity of Glutaraldehyde at Low Concentrations (< 2%) against Poliovirus and its Relevance to Gastrointestinal Endoscope Disinfection Procedures, *Applied and Environmental Microbiology.* April, 1991.
11. Proposed Recommended Practices for Chemical Disinfection, *AORN J.* 1994;464.

**Johnson & Johnson**  
**MEDICAL INC.**



# CHEMICAL GERMICIDES IN HEALTH CARE

Edited by:  
**William A. Rutala, Ph.D., M.P.H.**

320 pages, 6" x 9" Soft Cover  
ISBN: 0-921317-48-4

**Price: \$57.00**  
(U.S. Funds)  
plus \$8.00 postage and handling  
(AIR MAIL \$18.00)

**T**his publication contains twenty two state-of-the-art chapters which resulted from the International Symposium on Chemical Germicides in Health Care sponsored by the Association for Professionals in Infection Control and Epidemiology Inc. (APIC).

The focus of the text is to provide guidance on the use of chemical germicides in health care and a critical review of clinical and laboratory research associated with the regulation and use of chemical germicides in health care. It features the expertise and guidance of over twenty five leading authorities in the fields of antiseptics, disinfection and sterilization.

The current information in this publication is indispensable to infection control professionals and hospital epidemiologists and will serve as an excellent reference text for microbiologists and environmental scientists.

Make checks payable to: **Polyscience Publications Inc.**

Mail to:



P.O. Box 148 Morin Heights  
(Quebec) Canada J0R 1H0  
FAX: (514) 226-5866

or call: TEL.: (514) 226-5870 USA/CANADA: 1-800-840-5870

Date: .....

Name: .....

Affiliation: .....

Tel.: (        ) .....

Address: .....

City: .....


State/Prov.: .....

Zip/Postal code: .....

CUT HERE

# CUSTOM REPRINTS!

Let *Infection Control and Hospital Epidemiology* enhance your article with personally-designed reprints!



You can get more use out of the information you find in *Infection Control and Hospital Epidemiology* with article reprints. Now, SLACK Incorporated offers quality reprints in a choice of styles—you can custom-design your reprints on quality gloss paper in color or black and white.

This means you can give your article more impact with the power of color. And your reprints can be assembled into a bound booklet. Custom reprints from SLACK Incorporated give your articles a polished, professional look.

Order your reprints now in a choice of colors and in 8 1/2" x 11" or newspaper (11" x 15") sizes. The power of knowledge...the power of choice...*Infection Control and Hospital Epidemiology* article reprints.

FOR A FREE ESTIMATE, CALL CATHY WARK AT  
1-800-257-8290  
(in N.J., call 1-609-848-1000)

Available on a quotation basis. Minimum order is 100.

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY™

## CONTENTS

Continued from cover

### PRACTICAL HEALTHCARE EPIDEMIOLOGY

#### Hospital Epidemiology in Smaller Hospitals

JOHN M. BOYCE, MD

600

### READERS' FORUM

#### A Letter from Oliver Wendell Holmes, 1809-1894: In Memory of the Centennial of His Death

ELIZABETH C. GATHRIGHT

607

### EDITOR SOUGHT

599, 616

### MEDICAL NEWS

GINA PUGLIESE, MD

612

New TB Respirators Expected to Save Millions 555

Guidelines for Prevention of Intravascular Device-Related Infection 569

HICPAC Guidelines 576

Congress's Office of Technology Assessment Will Close 581

VRE Common 599

Court Rejects HIV-Positive Surgical Technician 606

PHS Guidelines for Prevention of Opportunistic Infections 611

Delays in Identification of *M tuberculosis* 612

Two Cases of HIV-2 Detected Among Blood Donors in US 612

ACIP Expands Hepatitis B Recommendations 612

Topical Microbicides to Prevent STD 613

### SHEA NEWS

C. GLEN MAYHALL, MD

616

SHEA Announces New Course on Clinical Epidemiology and Quality Improvement 616

THE PUBLICATION OF ADVERTISING IN THE JOURNAL DOES NOT CONSTITUTE ANY GUARANTEE OR ENDORSEMENT BY THE SOCIETY FOR HEALTHCARE EPIDEMIOLOGY OF AMERICA OR SLACK INCORPORATED OF THE ADVERTISED PRODUCT OR SERVICE OR OF CLAIMS MADE BY THE ADVERTISER. THE PUBLICATION OF ARTICLES AND OTHER EDITORIAL MATERIAL IN THE JOURNAL DOES NOT NECESSARILY REPRESENT THE POLICY RECOMMENDATIONS OR ENDORSEMENT BY THE SOCIETY.

**PUBLISHER:** Infection Control and Hospital Epidemiology (ISSN-0899-823X, Canadian GST#129780466) is published exclusively by SLACK Incorporated 12 times a year. Address: 6900 Grove Rd., Thorofare, NJ 08086. Telephone: (609) 848-1000.

**COPYRIGHT 1995** The Society for Healthcare Epidemiology of America, Inc., and SLACK Incorporated. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. Printed in the USA.

**SUBSCRIPTIONS:** Requests should be addressed to the publisher (except Japan). In Japan, contact Woodbell Incorporated, 4-22-11, Kitakasai, Edogawaku, Tokyo 134, Japan. Subscription rates in the United States and possessions: Individual: One year-\$95.00; Two years-\$130.00; Three years-\$160.00; Institutional: One year-\$105.00; Two years-\$145.00; Three years-\$185.00. Fellows: \$35 per year with proof of training status. Canada: \$18.00 additional each year plus 7% for Canadian Goods & Services tax; all other countries: \$36.00 additional each year. Single copies of current issues may be obtained for \$15.00, United States and possessions; \$30.00 all other countries.

**REPRINTS:** All requests to reprint or use material published herein should be addressed to Dan Boyden, SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086. For reprint orders and prices, contact Dan Boyden at (609) 848-1000. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by SLACK Incorporated, provided that the base fee of \$1.00 per copy, plus \$.15 per page is paid directly to Copyright Clearance Center, 27 Congress St., Salem, MA 01970. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotional purposes, or for creating new collective works.

**CHANGE OF ADDRESS:** Notice should be sent to the publisher six weeks in advance of effective date. Include old and new addresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Second-class postage is paid at Thorofare, New Jersey 08086, and additional entry points. POSTMASTER: Send address changes to SLACK Incorporated, 6900 Grove Rd., Thorofare, NJ 08086.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY is listed in Index Medicus, Current Contents-Clinical Practice, Hospital Literature Index, Cumulative Index to Nursing & Allied Health Literature, Nursing Abstracts, Laboratory Performance Information Exchange System, and RnDex Top 100.

Editorial Offices  
Vanderbilt University School of Medicine  
A-1131 Medical Center North  
Nashville, TN 37232-2637  
(615) 343-1095; (615) 343-1882 (FAX)

**EDITOR**

Michael D. Decker, MD, MPH

**MANAGING EDITOR**

Susan Cantrell

**STATISTICAL EDITOR**

George W. Reed, PhD

**EDITORIAL COMMITTEE**

Martin J. Blaser, MD  
David W. Gregory, MD  
Allen B. Kaiser, MD  
Douglas S. Kernodle, MD  
Robert H. Latham, MD  
Lewis B. Lefkowitz, MD  
Charles W. Stratton, MD  
Clyde Thornberry, PhD

**SENIOR ASSOCIATE EDITORS**

Donald A. Goldmann, MD  
C. Glen Mayhall, MD  
William Schaffner, MD

**ASSOCIATE EDITOR**

Sue Crow, MSN, RN, CIC

**SECTION EDITORS****AIDS**

David K. Henderson, MD  
Bethesda, Maryland

**Beyond Infection Control:**

The New Hospital Epidemiology  
Bryan P. Simmons, MD  
Stephen B. Kritchevsky, PhD  
Memphis, Tennessee

**Global Aspects of Infection Control**

Mary D. Nettleman, MD  
Iowa City, Iowa

**Issues in Surgery**

James T. Lee, MD, PhD  
Minneapolis, Minnesota

**Medical News**

Gina Pugliese, RN, MS  
Chicago, Illinois

**Molecular Hospital Epidemiology**

Neil L. Barg, MD  
Ann Arbor, Michigan

**Organizations Pertinent to Infection Control**

Marguerite McMillan Jackson, RN, MS  
San Diego, California

**Practical Healthcare Epidemiology**

Loreen A. Herwaldt, MD  
Iowa City, Iowa

**Product Commentary**

Sue Crow, MSN, RN, CIC  
Shreveport, Louisiana

**SHEA News**

C. Glen Mayhall, MD  
Galveston, Texas

**Statistics for Hospital Epidemiology**

David Birnbaum, PhD, MPH  
Sidney, British Columbia, Canada

**Topics in Clinical Microbiology**

Charles W. Stratton, MD  
Nashville, Tennessee

**Topics in Long-Term Care**

David W. Bentley, MD  
Buffalo, New York

**Topics in Occupational Medicine**

William A. Rutala, PhD, MPH  
David Weber, MD, MPH  
Chapel Hill, North Carolina

**Tuberculosis**

Michael L. Tapper, MD  
New York, New York

# INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY<sup>®</sup>

## EDITORIAL ADVISORY BOARD

J. Wesley Alexander, MD	Cincinnati, Ohio
Paul Arnow, MD	Chicago, Illinois
Elizabeth Ann Bolyard, RN, MPH, CIC	Atlanta, Georgia
Donald E. Craven, MD	Boston, Massachusetts
Richard E. Dixon, MD, FACP	Berkeley, California
Leigh G. Donowitz, MD	Charlottesville, Virginia
Theodore C. Eickhoff, MD	Denver, Colorado
Bruce Farber, MD	Manhasset, New York
Martin S. Favero, PhD	Atlanta, Georgia
Peter C. Fuchs, MD, PhD	Portland, Oregon
Richard A. Garibaldi, MD	Farmington, Connecticut
Peter N.R. Heseltine, MD	Los Angeles, California
Karen Hoffmann, RN, CIC, MS	Chapel Hill, North Carolina
Janine Jagger, MPH, PhD	Charlottesville, Virginia
Victor Lorian, MD	Bronx, New York
Dennis G. Maki, MD	Madison, Wisconsin
William J. Martone, MD	Atlanta, Georgia
John E. McGowan, Jr., MD	Atlanta, Georgia
Michael T. Osterholm, PhD, MPH	Minneapolis, Minnesota
Michael A. Pfaller, MD	Portland, Oregon
William E. Scheckler, MD	Madison, Wisconsin
Walter E. Stamm, MD	Seattle, Washington
Timothy R. Townsend, MD	Baltimore, Maryland
Robert A. Weinstein, MD	Chicago, Illinois

## INTERNATIONAL ADVISORY BOARD

Jacques F. Acar, MD	Paris, France
George Berencsi, MD	Szeged, Hungary
Christian Brun-Buisson, MD	Creteil, France
Franz Daschner, MD	Freiburg, Federal Republic of Germany
Velj Greene, PhD, MPH	Beer Sheva, Israel
Professor Wlodzimierz B. Kedzia	Sieroca, Poland
Professor Alexi P. Krasilnikow	Minsk, USSR
Hsieh-Shong Leu, MD, MSc	Taipei, Taiwan
Jack Levy, MD	Brussels, Belgium
Professor Dr. Walter Marget	Munich, Federal Republic of Germany
Jonathan L. Meakins, MD, DSc	Montreal, Canada
Bertil Nystrom, MD	Huddinge, Sweden
Juhani Ojajorvi, MD	Helsinki, Finland
Ian Phillips, MA, MD, MRCPath	London, England
Didier Pittet, MD, MS	Geneva, Switzerland
Samuel Ponce de Leon, MD, MSc	Mexico City, Mexico
Hans Reber, MD	Basel, Switzerland
Manfred L. Rotter, MD, DipBact	Vienna, Austria
Theodore Sacks, MD	Jerusalem, Israel
Denis Spelman, MD	Victoria, Australia
Dr. Bernhard M. Thimm	Ulm, Federal Republic of Germany
Antoni Trilla, MD, PhD	Barcelona, Spain
Professor Dr. med. H.P. Werner	Mainz, Federal Republic of Germany
Professor Dr. W. Weuffen	Greifswald, Federal Republic of Germany
Sergio B. Wey, MD	Sao Paulo, Brazil
Andreas Widmer, MD	Basel, Switzerland

**SLACK Incorporated**  
6900 Grove Road  
Thorofare, New Jersey 08086  
(609) 848-1000

**Vice President/Group Publisher**

Richard N. Roash

**Publisher**

John C. Carter

**Editorial Director**

Jennifer Kilpatrick

**Managing Editor**

Dawn Duperre

**Associate Editor**

Lillian Goldy

**Circulation Manager**

Lester J. Robeson

**Production Manager**

Chris Dorsen

**Production Coordinator**

Joanne Patterson

**Publishing Director/Advertising**

Wayne McCourt

**Advertising Sales**

Coordinator

**Michael LoPresti**

Classified Advertising

**Representative**

Donna Rosenstock